← boardnext 2027-01
COYA
Coya Therapeuticsdistress 3/10 · well-funded / low risk$4.30-2%today-42% from 52w high
Lead: Amyotrophic Lateral Sclerosis (ALS)
Revenue
pre-revenue
Liquidity
$51M
Runway
3.6 yrs
Shares 1y
+40%
Price & events
-9.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
-6.6%
1W
-20.3%
1M
-1.0%
3M
-8.9%
6M
-29.2%
1Y
-40.1%
2Y
—
5Y
-6.0%
All
Overview
- Market Cap
- $100.82M
- Volume
- 14.41K
- 52 Week Range
- $3.78 – $7.36
- Total Shares
- 23.46M
- Float Shares
- 17.54M
- Short %
- 3.94%
- % Held by Insiders
- 14.69%
- % Held by Institutions
- 35.37%
- RVOL
- 0.06x
- Beta
- 0.51
Pipeline stages · 1 programs
COYA 302
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01 Estimated 50% readout ~2027-02-15 | Phase 2 | COYA 302fast track | Amyotrophic Lateral Sclerosis (ALS) | — | recruiting |
Catalyst news & presentations · 20
- 1Q 2027Guided 70%readoutPhase 2COYA 302 · Topline readout of ALSTARS Phase 2 trialSEC 8-K
- first quarter of 2027Guided 70%readoutPhase 2Topline data from ALSTARS Phase 2 trialSEC 8-K
- 2H 2026Guided 55%trial initiationsecondaryPhase 2COYA 302 · Initiate Phase 2a study for FTDSEC 8-K
- 2H 2026Guided 55%enrollment completesecondaryPhase 2COYA 302 · Target full enrollment of ALSTARS Phase 2 trialSEC 8-K
- 2H 2026Guided 55%conferencedata presentationsecondaryCOYA 303 · Publication of COYA 303 in vivo dataSEC 8-K
- 2H 2026Guided 55%conferencedata presentationsecondaryReport additional single cell proteomics data from ALS and AD trialsSEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- June 2026conferencedata presentationsecondaryScientific presentations at ALS Drug Development Summit and ENCALSSEC 8-K
- 2026-05-11fda agreementCOYA 302 · FDA cleared amended ALSTARS protocol to broaden patient populationSEC 8-K
- 2026-01-29partnershipCOYA 302 · Dr. Reddy's Labs invests $10M in private placement as strategic collaborator.SEC 8-K
- 2025conferencedata presentationsecondaryPhase 2COYA 301 · Additional single cell proteomics data from Phase 2 studySEC 8-K
- Q4 2025regulatory submissionFiled (NDA/BLA)COYA 302 · IND submission for FTD anticipatedSEC 8-K
- 2025-12-16partnershipCOYA 302 · Milestone payment of $4.2M triggered by first patient dosing in ALSTARS trial for ALS.SEC 8-K
- 2025-10-01fda agreementCOYA 302 · FDA accepted IND for COYA 302 in ALSSEC 8-K
- 2025-08-29partnershipCOYA 302 · Received $4.2M milestone payment from Dr. Reddy's due to IND acceptanceSEC 8-K
- 2025-08-29fda agreementCOYA 302 · FDA accepted IND for Phase 2 study of COYA 302 in ALSSEC 8-K
- no later than August 29, 2025filing acceptanceFiled (NDA/BLA)COYA 302 · FDA to decide on IND for Phase 2 study of COYA 302 in ALSSEC 8-K
- 2025-07-29pdufa extensionCOYA 302 · FDA unable to meet initial IND review goal of July 30, 2025; expects decision by August 29, 2025SEC 8-K
- 2Q 2025regulatory submissionFiled (NDA/BLA)COYA 302 · FDA IND submission for Phase 2 trial in ALSSEC 8-K
- 2024-07-12clinical holdCOYA 302 · FDA required additional non-clinical data prior to initiation of Phase 2 study in ALSSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $15 (+254% upside) · 7 analysts
- 2026-06-12Chardan CapitalBuy
- 2026-06-05Roth CapitalBuy
- 2026-04-10D. Boral CapitalBuy
- 2026-03-23HC Wainwright & Co.Buy
- 2026-03-19D. Boral CapitalBuy
- 2026-03-16D. Boral CapitalBuy
Competitors — Amyotrophic Lateral Sclerosis (ALS)
- none identified
Recent news
- 2026-07-22Discipline and Rules-Based Execution in COYA Response - Stock Traders Daily
- 2026-07-20Coya Ibiza is bringing grown-up hedonism to Playa d’en Bossa - MSN
- 2026-07-19Price to book forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
- 2026-07-18Coya Therapeutics (COYA) Dips 1.3% as Stock Tests Key Support Levels - Bear Pennant - dars.gov.et
- 2026-07-17Coya Ibiza is bringing grown-up hedonism to Playa d’en Bossa - City AM
- 2026-07-16Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target - Streetwise Reports
- 2026-07-16Houston ALS Biotech Coya Eyes 2028 Approval Path - Streetwise Reports
- 2026-07-14Coya, Cusco, PE Simulated Weather Radar Map - WeatherBug
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.